A third monoclonal antibody product to protect babies against respiratory syncytial virus was approved by the Food and Drug Administration on Monday, a development public health experts hope may ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

The monoclonal antibody reduced the incidence of RSV-associated medically attended lower respiratory infections that had at least one indicator of lower respiratory infection or severity by 60.5% ...

Migratory birds develop antibodies to bird flu, officials say by: Karina F. Garcia Posted: Jun 6, 2025 / 06:33 PM EDT Updated: Jun 6, 2025 / 06:34 PM EDT ...

Breakthrough Trispecific Antibody Shows Strong Early Efficacy: JNJ-5322 demonstrated an 86.1% overall response rate (ORR) at the recommended Phase II dose in heavily pretreated multiple myeloma ...

Antibodies are secreted immunoglobulin molecules produced mainly by plasma cells. The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody ...

“Consistent with what we previously demonstrated in animal models, these clinical data prove that our second-generation constructs increased antibody titers in humans, providing additional ...

Based on several lines of interesting data, the authors conclude that FMRP, though associated with stalled ribosomes, does not determine the position on the mRNAs at which ribosomes stall. Although ...

An overview of the articles in this Focus issue on therapeutic antibodies. Over the past 10 years, the market for monoclonal antibodies has grown exponentially. This focus issue brings together ...

AUSTIN, Texas, June 12, 2025--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that ...

Big pharma companies like Pfizer are making significant investments in antibody-drug conjugates, a promising class of therapies. This article explores the growing interest and recent developments ...